EP4 receptor agonist 3 prodrug
EP4 receptor agonist 3 prodrug (Compound 9) is a prodrug of EP4 receptor agonist (Compound 1a) . EP4 receptor agonist 3 prodrug itself has no agonistic activity on the EP4 receptor and needs to be specifically hydrolyzed by intestinal alkaline phosphatase (IAP) in the intestine to release the active molecule, which then exerts the EP4 receptor agonistic effect locally in the intestine. EP4 receptor agonist 3 prodrug has colonic targeting properties and significantly alleviates colitis in mice[1].
Product Specifications
UNSPSC
12352005
Target
Drug Derivative
Related Pathways
Others
Field of Research
Inflammation/Immunology
Smiles
FC([C@H](OCCP(O)(O)=O)/C=C/[C@@H]1N(CCCCCCC(O)=O)C(CC1)=O)(F)C2=CC=CC=C2
Molecular Formula
C23H32F2NO7P
Molecular Weight
503.47
References & Citations
[1]Kantham S, et al. Development of novel GI-centric prostaglandin E2 receptor type 4 (EP4) agonist prodrugs as treatment for ulcerative colitis and other intestinal inflammatory diseases. Bioorg Med Chem Lett. 2025 Apr 15;119:130093.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040178-500 1x 500 µL
CD50 (ICAM-3) (186-2G9), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040034-100 1x 100 µL
Cytokeratin 8/18 (C-51), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 